EYEN vs. PRPH, PHIO, ACXP, MYNZ, TSBX, BCLI, RLMD, TXMD, NEUP, and ABVC
Should you be buying Eyenovia stock or one of its competitors? The main competitors of Eyenovia include ProPhase Labs (PRPH), Phio Pharmaceuticals (PHIO), Acurx Pharmaceuticals (ACXP), Mainz Biomed (MYNZ), Turnstone Biologics (TSBX), Brainstorm Cell Therapeutics (BCLI), Relmada Therapeutics (RLMD), TherapeuticsMD (TXMD), Neuphoria Therapeutics Inc. - Common Stock (NEUP), and ABVC BioPharma (ABVC). These companies are all part of the "pharmaceutical products" industry.
Eyenovia vs.
ProPhase Labs (NASDAQ:PRPH) and Eyenovia (NASDAQ:EYEN) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, valuation, institutional ownership, earnings, analyst recommendations, dividends, community ranking, profitability and media sentiment.
9.4% of ProPhase Labs shares are held by institutional investors. Comparatively, 25.8% of Eyenovia shares are held by institutional investors. 20.7% of ProPhase Labs shares are held by insiders. Comparatively, 7.1% of Eyenovia shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
ProPhase Labs has a net margin of -217.64% compared to Eyenovia's net margin of -114,639.41%. ProPhase Labs' return on equity of -62.92% beat Eyenovia's return on equity.
Eyenovia has a consensus price target of $2.00, suggesting a potential upside of 50.38%. Given Eyenovia's stronger consensus rating and higher probable upside, analysts plainly believe Eyenovia is more favorable than ProPhase Labs.
Eyenovia received 60 more outperform votes than ProPhase Labs when rated by MarketBeat users. Likewise, 64.21% of users gave Eyenovia an outperform vote while only 48.93% of users gave ProPhase Labs an outperform vote.
ProPhase Labs has a beta of -0.53, suggesting that its share price is 153% less volatile than the S&P 500. Comparatively, Eyenovia has a beta of 1.29, suggesting that its share price is 29% more volatile than the S&P 500.
ProPhase Labs has higher revenue and earnings than Eyenovia. ProPhase Labs is trading at a lower price-to-earnings ratio than Eyenovia, indicating that it is currently the more affordable of the two stocks.
In the previous week, Eyenovia had 7 more articles in the media than ProPhase Labs. MarketBeat recorded 9 mentions for Eyenovia and 2 mentions for ProPhase Labs. Eyenovia's average media sentiment score of 0.01 beat ProPhase Labs' score of 0.00 indicating that Eyenovia is being referred to more favorably in the news media.
Summary
Eyenovia beats ProPhase Labs on 10 of the 17 factors compared between the two stocks.
Get Eyenovia News Delivered to You Automatically
Sign up to receive the latest news and ratings for EYEN and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Eyenovia Competitors List
Related Companies and Tools
This page (NASDAQ:EYEN) was last updated on 3/25/2025 by MarketBeat.com Staff
Buy EYEN Stock Free EYEN Stock Alerts